Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities: 2012-2025

Historic Preferred Stock Liabilities for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $1.3 million.

  • Enanta Pharmaceuticals' Preferred Stock Liabilities fell 2.89% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 2.89%. This contributed to the annual value of $1.3 million for FY2025, which is 2.89% down from last year.
  • As of FY2025, Enanta Pharmaceuticals' Preferred Stock Liabilities stood at $1.3 million, which was down 2.89% from $1.4 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Preferred Stock Liabilities ranged from a high of $1.5 million in FY2021 and a low of $1.3 million during FY2025.
  • Over the past 3 years, Enanta Pharmaceuticals' median Preferred Stock Liabilities value was $1.4 million (recorded in 2024), while the average stood at $1.4 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Preferred Stock Liabilities climbed by 1.83% in 2021 and then declined by 5.51% in 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' Preferred Stock Liabilities (Yearly) stood at $1.5 million in 2021, then declined by 5.51% to $1.4 million in 2022, then remained steady at $1.4 million in 2023, then dropped by 5.13% to $1.4 million in 2024, then decreased by 2.89% to $1.3 million in 2025.